Abstract:Background and Purpose-Intravenously delivered human umbilical cord blood cells (HUCBC) have been previouslyshown to improve functional recovery of stroked rats. To extend these findings, we examined the behavioral recovery and stroke infarct volume in the presence of increasing doses of HUCBC after permanent middle cerebral artery occlusion (MCAO). Methods-Rats were subjected to MCAO and allowed to recover for 24 hours before intravenous infusion of 10 4 up to 3 to 5ϫ10 7 HUCBC. Behavioral tests (spontaneous … Show more
“…On the other hand, systemic transplantation of NPCs mediates acute neuroprotection from the luminal side of the vessels for which high intracerebral cell numbers seem to be not necessary. This observation is in line with previous reports where systemic transplantation of stem and precursor cells initiated beneficial effects despite low cell numbers or even no detectable cells within the ischemic brain [60][61][62][63].…”
Novel therapeutic concepts against cerebral ischemia focus on cell-based therapies in order to overcome some of the side effects of thrombolytic therapy. However, cell-based therapies are hampered because of restricted understanding regarding optimal cell transplantation routes and due to low survival rates of grafted cells. We therefore transplanted adult green fluorescence protein positive neural precursor cells (NPCs) either intravenously (systemic) or intrastriatally (intracerebrally) 6 hours after stroke in mice. To enhance survival of NPCs, cells were in vitro protein-transduced with TAT-heat shock protein 70 (Hsp70) before transplantation followed by a systematic analysis of brain injury and underlying mechanisms depending on cell delivery routes. Transduction of NPCs with TAT-Hsp70 resulted in increased intracerebral numbers of grafted NPCs after intracerebral but not after systemic transplantation. Whereas systemic delivery of either native or transduced NPCs yielded sustained neuroprotection and induced neurological recovery, only TAT-Hsp70-transduced NPCs prevented secondary neuronal degeneration after intracerebral delivery that was associated with enhanced functional outcome. Furthermore, intracerebral transplantation of TAT-Hsp70-transduced NPCs enhanced postischemic neurogenesis and induced sustained high levels of brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, and vascular endothelial growth factor in vivo. Neuroprotection after intracerebral cell delivery correlated with the amount of surviving NPCs. On the contrary, systemic delivery of NPCs mediated acute neuroprotection via stabilization of the blood-brain-barrier, concomitant with reduced activation of matrix metalloprotease 9 and decreased formation of reactive oxygen species. Our findings imply two different mechanisms of action of intracerebrally and systemically transplanted NPCs, indicating that systemic NPC delivery might be more feasible for translational stroke concepts, lacking a need of in vitro manipulation of NPCs to induce long-term neuroprotection.
“…On the other hand, systemic transplantation of NPCs mediates acute neuroprotection from the luminal side of the vessels for which high intracerebral cell numbers seem to be not necessary. This observation is in line with previous reports where systemic transplantation of stem and precursor cells initiated beneficial effects despite low cell numbers or even no detectable cells within the ischemic brain [60][61][62][63].…”
Novel therapeutic concepts against cerebral ischemia focus on cell-based therapies in order to overcome some of the side effects of thrombolytic therapy. However, cell-based therapies are hampered because of restricted understanding regarding optimal cell transplantation routes and due to low survival rates of grafted cells. We therefore transplanted adult green fluorescence protein positive neural precursor cells (NPCs) either intravenously (systemic) or intrastriatally (intracerebrally) 6 hours after stroke in mice. To enhance survival of NPCs, cells were in vitro protein-transduced with TAT-heat shock protein 70 (Hsp70) before transplantation followed by a systematic analysis of brain injury and underlying mechanisms depending on cell delivery routes. Transduction of NPCs with TAT-Hsp70 resulted in increased intracerebral numbers of grafted NPCs after intracerebral but not after systemic transplantation. Whereas systemic delivery of either native or transduced NPCs yielded sustained neuroprotection and induced neurological recovery, only TAT-Hsp70-transduced NPCs prevented secondary neuronal degeneration after intracerebral delivery that was associated with enhanced functional outcome. Furthermore, intracerebral transplantation of TAT-Hsp70-transduced NPCs enhanced postischemic neurogenesis and induced sustained high levels of brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, and vascular endothelial growth factor in vivo. Neuroprotection after intracerebral cell delivery correlated with the amount of surviving NPCs. On the contrary, systemic delivery of NPCs mediated acute neuroprotection via stabilization of the blood-brain-barrier, concomitant with reduced activation of matrix metalloprotease 9 and decreased formation of reactive oxygen species. Our findings imply two different mechanisms of action of intracerebrally and systemically transplanted NPCs, indicating that systemic NPC delivery might be more feasible for translational stroke concepts, lacking a need of in vitro manipulation of NPCs to induce long-term neuroprotection.
“…[89][90][91][92][93][94][95][96] Beneficial effects have generally been observed determined by behavioral improvements in most cases, but also by the reduction in lesion size in some studies. Owing to the poor survival of the transplanted cells and little evidence for neural differentiation, bystander effects have been postulated to be the main mechanisms for functional recovery after CB transplantation, including release of neurotrophic factors to stimulate endogenous neurogenesis, prevention of cell loss and immunomodulation (Figure 4).…”
Section: Animal Models Of Human Cb Transplantation For Hiementioning
Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the risk of death or major neurological disabilities among neonates with HIE. However, in these trials, approximately 40% of cooled infants died or survived with significant impairments. Therefore, adjunct therapies are required to improve the outcome in neonates with HIE. Cord blood (CB) is a rich source of stem cells. Administration of human CB cells in animal models of HIE has generally resulted in improved outcomes and multiple mechanisms have been suggested including anti-inflammation, release of neurotrophic factors and stimulation of endogenous neurogenesis. Investigators at Duke are conducting studies of autologous CB infusion in neonates with HIE and in children with cerebral palsy. These pilot studies indicate no added risk from the regimens used, but results of ongoing placebo-controlled trials are needed to assess efficacy. Meanwhile, further investigations are warranted to determine the best strategies, that is, timing, dosing, route of delivery, choice of stem cells and ex vivo modulations, to attain long-term benefits of CB stem cell therapy.
“…Cord blood cells can be expanded in culture and induced to differentiate into cells with neural markers. 37 Recently, cord blood cells have been shown to improve functional recovery in rats that have been subjected to strokes, by middle cerebral artery occlusion. Infarct volume was reduced and behavioral performance increased when a higher dose of cells was infused.…”
During human development, stem cells establish themselves in specific anatomic locations or niches. The niche harbors the stem cells, and regulates how stem cells proliferate. The interaction between stem cells and their niche affects stem cell function, and offers an opportunity to improve the marrow microenvironment. Osteoblasts produce hematopoietic growth factors and are activated by parathyroid hormone (PTH). A calcium sensing receptor, expressed by hematopoietic stem cells, regulates the niche and can be targeted to increase stem cell numbers. Therefore, drugs that affect osteoblast function or target calcium receptors may be useful for stem cell mobilization and engraftment. In this review, the biology of the stem cell niche and the potential therapeutic manipulations of the stem cell niche are reviewed. PTH is in clinical trials for patients who have not mobilized autologous stem cells well. The limiting cell numbers for adult cord blood transplantation increase the risk of infection, and PTH is currently in a clinical trial following cord blood transplantation in an effort to improve engraftment and immune reconstitution. The word niche comes from the French; the literal meaning is a doghouse. The niche is not just a place, but has a functional dimension. For example, hematopoietic stem cells (HSCs) require a specific microenvironment for selfreplication. The first example of the niche as specialized microenvironment was demonstrated in Drosophila. 1 In the Drosophila ovary, germ line stem cells maintain oocyte production. A small group of somatic cells located at the tip of the ovariole form a tubular structure that maintains and controls germ line stem cells. The cap cells may allow stem cells to adhere to the niche.
The hematopoietic stem cell nicheThe HSC niche is a dynamic system. Cells, matrix glycoprotein and three-dimensional spaces provide the ultrastructure for a stem cell niche. HSCs circulate but do not function outside of specific locations. The ability of the niche to contribute to stem cell function makes the concept of the niche important for understanding human disease. Schofield and colleagues proposed the niche hypothesis; HSCs exist in a microenvironment; the microenvironment cells confer upon the HSCs self-renewal capabilities. 2 Recently, the osteoblasts have been found to be important components of the niche. Osteopontin is a sialoprotein that interacts with receptors on HSCs, such as CD44, alpha4 and alpha5 beta1 integrins. 3,4 Osteopontin production varies with osteoblast activation and osteopontin serves to limit stem cell numbers. Osteopontin expression contributes to the migration of HSCs toward the endosteal region. Without osteopontin, increased stem cell expansion can occur. Bone also has a high concentration of calcium ions at the endosteal surface, a surface rich in HSCs. 5 A calcium sensing receptor, expressed by HSCs, acts as a regulatory component of the HSC niche. The calcium sensing receptor is a potential target to manipulate the niche and increase stem cell number...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.